期刊
BRITISH JOURNAL OF ANAESTHESIA
卷 117, 期 5, 页码 559-568出版社
ELSEVIER SCI LTD
DOI: 10.1093/bja/aew321
关键词
cardiovascular diseases; mortality; myocardial ischaemia; perioperative period; postoperative complications; troponin
资金
- Abbott Diagnostics
- Astra Zeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Covidien
- Octapharma
- Philips Healthcare
- Roche Diagnostics
- Stryker
Background: Patients undergoing non-cardiac, non-vascular surgery are at risk of major cardiovascular complications. In non-cardiac surgery, troponin elevation has previously been shown to be an independent predictor of major adverse cardiac events and postoperative mortality; however, a majority of studies have focused on vascular surgery patients. The aim of this meta-analysis was to determine whether troponin elevation is a predictor of major adverse cardiac events and mortality within 30 days and 1 yr after non-cardiac, non-vascular surgery. Methods: A systematic review and meta-analysis was conducted in January 2016 according to the Meta-analysis Of Observational Studies in Epidemiology guidelines. Both interventional and observational studies measuring troponin within the first 4 days after surgery were eligible. A systematic search was performed in PubMed, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials. Results: Eleven eligible clinical studies (n=2193) were identified. A postoperative troponin elevation was a predictor of 30 day mortality, odds ratio (OR) 3.52 [95% confidence interval (CI) 2.21-5.62; I-2=0%], and an independent predictor of 1 yr mortality, adjusted OR 2.53 (95% CI 1.20-5.36; I-2=26%). A postoperative troponin elevation was associated with major adverse cardiac events at 30 days, OR 5.92 (95% CI 1.67-20.96; I-2=86%), and 1 yr after surgery, adjusted OR 3.00 (95% CI 1.43-6.29; I-2=21%). Conclusions: Postoperative myocardial injury is an independent predictor of major adverse cardiac events and mortality within 30 days and 1 yr after non-cardiac, non-vascular surgery. The meta-analysis provides evidence that supports troponin monitoring as a cardiovascular risk stratification tool.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据